0001104659-23-077110.txt : 20230630 0001104659-23-077110.hdr.sgml : 20230630 20230630161122 ACCESSION NUMBER: 0001104659-23-077110 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProSomnus, Inc. CENTRAL INDEX KEY: 0001934064 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-269156 FILM NUMBER: 231061825 BUSINESS ADDRESS: STREET 1: 5675 GIBRALTAR AVENUE CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: 844-537-5337 MAIL ADDRESS: STREET 1: 5675 GIBRALTAR AVENUE CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: LAAA Merger Corp. DATE OF NAME CHANGE: 20220615 424B3 1 tm2320309d2_424b3.htm 424B3

 

PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated June 2, 2023) Registration No. 333-269156

 

Prosomnus, Inc.

 

 

 

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 2, 2023 (the “Prospectus”) filed by ProSomnus, Inc. (the “Company”) with the information contained in the Company’s Current Report on Form 8-K, filed with the SEC on June 30, 2023. Accordingly, we have attached such Current Report on Form 8-K to this prospectus supplement.

 

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

 

Our common stock and our public warrants are listed on the Nasdaq Global Market and Nasdaq Capital Market, respectively, under the symbols “OSA” and “OSAAW,” respectively. On June 29, 2023, the closing price of our common stock was $3.45 and the closing price for our public warrants was $0.10.

 

We are an “emerging growth company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements.

 

Investing in our securities is highly speculative and involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 13 of the Prospectus.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus supplement is June 30, 2023.

 

 

 

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 29, 2023

 

PROSOMNUS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41567   88-2978216
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

5675 Gibraltar Avenue    
Pleasanton, CA   94588
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (844) 537-5337

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  Trading Symbol(s)  Name of each exchange on
which registered
Common Stock, par value $0.0001 per share  OSA  The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share  OSAAW  The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement

 

First Supplemental Indenture to Convertible Senior Notes Indenture

 

On June 29, 2023, ProSomnus, Inc. (the “Company”) entered into the First Supplemental Indenture (the “Senior Supplemental Indenture”) to that certain Indenture, dated December 6, 2022, by and among the Company, ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc., as guarantors, and Wilmington Trust, National Association, as trustee and collateral agent (as amended, the “Senior Indenture”), pursuant to which the Company issued its Senior Secured Convertible Notes due December 6, 2025 (the “Senior Convertible Notes”). The Senior Supplemental Indenture amends the Senior Indenture to, among other things, (i) make certain changes to the minimum EBITDA and minimum revenue financial covenants in the Senior Indenture, (ii) require mandatory redemption of the Senior Convertible Notes (as described below) and (iii) make certain other revisions as more fully set forth therein.

 

Pursuant to the Senior Indenture, as amended, the Company shall redeem the Senior Convertible Notes in consecutive quarterly installments equal to $847,990 in the aggregate on January 1, April 1, July 1 and October 1 of each year, commencing October 1, 2024, until the earlier of the maturity date of the Senior Convertible Notes or the date the Senior Convertible Notes are no longer outstanding.

 

The description of the Senior Supplemental Indenture is qualified in its entirety by reference to the text of the Senior Supplemental Indenture, which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

First Supplemental Indenture to Subordinated Notes Indenture

 

On June 29, 2023, the Company entered into the First Supplemental Indenture (the “Subordinated Supplemental Indenture”) to that certain Indenture, dated December 6, 2022, by and among the Company, ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc., as guarantors, and Wilmington Trust, National Association, as trustee and collateral agent (as amended, the “Subordinated Indenture”), pursuant to which the Company issued its Subordinated Secured Convertible Notes due April 6, 2026. The Subordinated Supplemental Indenture amends the Subordinated Indenture to, among other things, (i) make certain changes to the minimum EBITDA and minimum revenue financial covenants in the Subordinated Indenture and (ii) make certain other revisions as more fully set forth therein.

 

The description of the Subordinated Supplemental Indenture is qualified in its entirety by reference to the text of the Subordinated Supplemental Indenture, which is filed as Exhibit 4.2 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 above is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
4.1   First Supplemental Indenture, dated as of June 29, 2023, by and among ProSomnus, Inc., ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc., as guarantors, and Wilmington Trust, National Association.
4.2   First Supplemental Indenture, dated as of June 29, 2023, by and among ProSomnus, Inc., ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc., as guarantors, and Wilmington Trust, National Association.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROSOMNUS, INC.
     
  By: /s/ Brian B. Dow
    Name: Brian B. Dow
    Title: Chief Financial Officer
     
Dated: June 30, 2023    

 

 

 

 

Exhibit 4.1

 

FIRST SUPPLEMENTAL INDENTURE

 

dated as of June 29, 2023

 

among

 

ProSomnus, Inc.,

 

the Subsidiary Guarantors Party Hereto

 

and

 

Wilmington Trust, National Association,
as Trustee and Collateral Agent

 

 

 

Senior Secured Convertible Notes due December 6, 2025

 

   

 

 

THIS FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), entered into as of June 29, 2023, among (i) ProSomnus, Inc., a Delaware corporation (the “Company”), (ii) ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc. (each, a “Subsidiary Guarantor”), and (iii) Wilmington Trust, National Association, as trustee (in such capacity, the “Trustee”) and collateral agent (“Collateral Agent”).

 

RECITALS

 

WHEREAS, the Company, the Subsidiary Guarantors party thereto and the Trustee and Collateral Agent entered into the Indenture, dated as of December 6, 2022 (the “Indenture”), relating to the Company’s Senior Secured Convertible Notes due December 6, 2025 (the “Notes”);

 

WHEREAS, the Company and the Holders of not less than a majority in aggregate principal amount of the Outstanding Notes desire to make certain amendments to the Indenture to, among other things, correct a scrivener’s error in the definition of Conversion Rate, and have delivered to the Company and the Trustee an Act of such Holders approving this First Supplemental Indenture; and

 

WHEREAS, pursuant to Section 8.02 of the Indenture, the Company, the Subsidiary Guarantors, the Trustee and the Collateral Agent are entering into this First Supplemental Indenture.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and intending to be legally bound, the parties to this First Supplemental Indenture hereby agree as follows:

 

Section 1. Defined Terms. Capitalized terms used herein and not otherwise defined herein are used as defined in the Indenture.

 

Section 2. Amendments to Indenture.

 

(a)           The definition of Consolidated EBITDA set forth in Section 1.01 of the Indenture is hereby amended and restated in its entirety as follows:

 

Consolidated EBITDA” means, for any applicable period, the sum of Consolidated Net Income (exclusive of all amounts in respect of any gains and losses realized from Dispositions other than inventory Disposed of in the ordinary course of business), (i) plus the sum, without duplication, of interest expense, depreciation, amortization, non-cash stock-based compensation expenses, any one-time moving expense, any losses from an early extinguishment of indebtedness, acquisition-related expenses, whether or not such acquisition is successful, non-cash changes in the valuation of assets and liabilities as required under GAAP and transaction fees, costs and expenses related to any issuance of equity or debt securities, whether or not successful, and (ii) minus the sum, without duplication, of operating expenses capitalized during such period and to be expensed in a future period to the extent that such expenses were not deducted in determining Consolidated Net Income and would have been deducted in determining Consolidated Net Income if they were not capitalized.

 

(b)           The definition of Conversion Rate set forth in Section 1.01 of the Indenture is hereby amended and restated in its entirety as follows:

 

Conversion Rate” means: 76.9230769231 shares of Common Stock per $1,000 of the sum of principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto,

 

   

 

 

subject to adjustment as set forth herein, which such Conversion Rate shall be increased and only increased on each Reset Date to equal the greater of (i) 76.9230769231 per $1,000 of the sum of the principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto, subject to adjustment as set forth herein, and (ii) the number of shares of Common Stock per $1,000 of the sum of the principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto obtained by dividing $1,000 by 105% of the applicable Market Price; provided, however, in no event shall the Conversion Rate be greater than 181.818181 per $1,000 of the sum of the principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto, subject to adjustment as set forth herein. The Company shall notify the Holders, the Trustee and the Conversion Agent of the applicable adjustment to the Conversion Rate as of such date (each notice, a “Reset Date Adjustment Notice”). For purposes of clarity, whether or not the Company provides a Reset Date Adjustment Notice, the Holders shall receive a number of shares of Common Stock and retain a principal amount of its Note, plus accrued interest thereon plus the Make-Whole Amount related thereto, based upon the Conversion Rate as adjusted pursuant to this definition, regardless of whether the Holder accurately refers to such Conversion Rate of principal amount of its Notes plus accrued interest thereon plus the Make-Whole Amount related thereto converted in any Conversion Notice. Any adjustment to the Conversion Rate shall be effective on the applicable Reset Date.

 

(c)          The definition of Outstanding set forth in Section 1.01 of the Indenture is hereby amended to amended and restate clause (iii)(B) therein as follows:

 

(B) Notes converted pursuant to Article 4 hereof, on and after their Conversion Date, and Notes redeemed pursuant to Section 2.01 or Article 10 hereof, on and after their applicable redemption date,

 

(d)           The definition of Permitted Indebtedness set forth in Section 1.01 of the Indenture is hereby amended and restated in its entirety as follows:

 

Permitted Indebtedness” means (a) the indebtedness evidenced by the Notes, (b) the Indebtedness existing on the Original Issue Date and set forth on Schedule 3.01(bb) attached to the Purchase Agreement, (c) lease obligations and purchase money indebtedness of up to $3,000,000, in the aggregate, incurred in connection with the acquisition of capital assets and lease obligations with respect to newly acquired or leased assets used in manufacturing the Company’s and its Subsidiaries’ products, (d) indebtedness that (i) is expressly subordinate to the Notes pursuant to a written subordination agreement with the Holders that is acceptable to each Holder in its sole and absolute discretion and (ii) matures at a date later than the 91st day following the Maturity Date, (e) financing for premiums on general business or director and officer insurance up to $3 million per calendar year, and (f) the Subordinated Debt.

 

(e)           The second paragraph of Section 2.01 of the Indenture is hereby amended and restated in its entirety as follows:

 

The Notes shall be known and designated as “Senior Secured Convertible Notes due 2025” of the Company. The Company shall repay to Holders the aggregate outstanding principal amount of the Notes in consecutive quarterly installments equal to $847,990 (each such payment, a “Mandatory Redemption”) on January 1, April 1, July 1 and October 1, commencing with October 1, 2024 (each, a “Mandatory Redemption Date”), until the earlier of the Maturity Date or the Notes no longer being Outstanding because earlier repaid, purchased or converted in accordance with this Indenture. The Outstanding principal amount of the Notes shall be payable on the Maturity Date.

 

   

 

 

In connection with any Mandatory Redemption, the Company shall deliver to the Trustee at least 15 Business Days prior to the applicable Mandatory Redemption Date (or such shorter period as shall be satisfactory to the Trustee) a notice of Mandatory Redemption and an Officer’s Certificate requesting the Trustee to deliver such notice to the Holders. Upon receipt of such Officer’s Certificate and notice of Mandatory Redemption, the Trustee shall deliver such notice of Mandatory Redemption to Holders of the Notes at least ten (10) Business Days before the Mandatory Redemption Date. Such notice shall be prepared by the Company and shall state (a) the Mandatory Redemption Date; (b) the aggregate principal amount of Notes to be mandatorily redeemed; (c) that, on Mandatory Redemption Date, the principal called for Mandatory Redemption will become due and payable; (d) that the Notes must be surrendered to the Paying Agent to collect the principal amount due to such Holder in connection with the Mandatory Redemption; (e) the place or places where such Notes are to be surrendered to the Paying Agent in connection with the Mandatory Redemption; (f) upon surrender of the Notes and consummation of the Mandatory Redemption, the aggregate principal amount of the Notes that will remain outstanding; and (g) that, upon surrender of a Holder’s Note in connection with such Mandatory Redemption, a new Note in principal amount equal to the unredeemed portion thereof shall be issued to such Holder. Any notice of Mandatory Redemption, if delivered in the manner herein provided, shall be conclusively presumed to have been duly given, whether or not the Holder receives such notice. In any case, failure to give such notice of Mandatory Redemption by mail or any defect in any such notice to the Holder of any Note designated for redemption as a whole or in part shall not affect the validity of the proceedings for the redemption of any other Note.

 

Regardless of whether the notice described in the preceding paragraph has been sent, the amount of the Notes subject to such Mandatory Redemption shall become due and payable at office of the Paying Agent on the Mandatory Redemption Date. On presentation and surrender of the Notes at the office of the Paying Agent, the Notes shall be paid and redeemed by the Company. Prior to the open of business on any Mandatory Redemption Date the Company shall deposit with the Trustee (or other Paying Agent appointed by the Company) or, if the Company or a subsidiary of the Company is acting as the Paying Agent, shall segregate and hold in trust as provided in Section 5.03(b), an amount of cash (in immediately available funds if deposited within three (3) Business Days prior to the Mandatory Redemption Date) sufficient to pay the amount of principal due on the Mandatory Redemption Date, plus accrued and unpaid interest thereon to, but excluding the Mandatory Redemption Date. Subject to receipt of funds by the Paying Agent, payment for the Notes to be redeemed shall be made on the Mandatory Redemption Date for such Notes.

 

In connection with a Mandatory Redemption, in the case of a Global Note, the Notes or portions thereof to be redeemed (in principal amounts of $1.00 or multiples thereof) shall be selected according to the applicable procedures of the Depositary, or, in the case of Physical Notes, the Notes to be redeemed (in principal amounts of at least $1.00 or $1.00 multiples in excess thereof) shall, upon written request of the Company, be selected by the Trustee by lot or by any other method the Trustee in its sole discretion deems fair and appropriate. The Company shall notify the Trustee in writing of the percentage of aggregate principal amount of the Notes Outstanding to be redeemed in connection with such Mandatory Redemption. The Trustee shall promptly notify the Company in writing of the Notes or portions of the Notes to be called for such Mandatory Redemption. If any Note selected for partial Mandatory Redemption is submitted for conversion after such selection, the portion of the Note submitted for conversion shall be deemed (so far as may be possible) to be the portion selected for such Mandatory Redemption (and the amount due in connection with such Mandatory Redemption will be reduced accordingly), subject, in the case of Notes represented by a Global Note, to the Depositary’s applicable procedures.

 

   

 

 

(f)            Section 5.17(a) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

(a)       Minimum EBITDA. The Company and its Subsidiaries shall not permit the Consolidated EBITDA as of the last day of any fiscal quarter of the Company, calculated for the period of four (4) consecutive fiscal quarters ended on such date, to be less than (i) for the fiscal quarters ending June 30, 2023, September 30, 2023 and December 31, 2023, ($12,500,000), (ii) for the fiscal quarters ending March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, ($10,000,000) and (iii) for the fiscal quarter ending March 3, 2025 and thereafter, ($7,500,000).

 

(g)           Section 5.17(b) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

(b)       Minimum Revenue. The Company and its Subsidiaries shall not permit the Revenue of the Company and its Subsidiaries on a consolidated basis in accordance with GAAP, as of the last day of any fiscal quarter ending on the dates set forth below and calculated for the period of the last twelve months ending on such date, to be less than the amount set forth below for such date.

 

Fiscal Quarter Ending Minimum Revenue
6/30/2023  $ 22,500,000
9/30/2023  $ 24,000,000
12/31/2023  $ 26,000,000
3/31/2024  $ 25,200,000
6/30/2024  $ 27,000,000
9/30/2024  $ 28,800,000
12/31/2024  $ 31,200,000
3/31/2025  $ 30,240,000
6/30/2025  $ 32,400,000
9/30/2025  $ 34,560,000
12/31/2025  $ 37,440,000

 

Section 3. Reference to and Effect on Indenture. On and after the effective date of this First Supplemental Indenture, each reference in the Indenture to “this Indenture,” “hereunder,” “hereof,” or “herein” shall mean and be a reference to the Indenture as amended and restated by this First Supplemental Indenture unless the context otherwise requires, and every Holder heretofore or hereafter authenticated and delivered shall be bound hereby.

 

Section 4. Reaffirmation. In connection with the execution and delivery of this First Supplemental Indenture, (a) the Company and each Grantor Subsidiary reaffirms, acknowledges, agrees and confirms that it has granted to the Collateral Agent, to the extent so required by and upon the terms set forth in the Senior Security Agreement, a security interest in the Collateral in order to secure all of its present and future Obligations and acknowledges and agrees that such security interest, and all Collateral heretofore pledged as security for the Obligations, continues to be and remains in full force and effect on and as of the date hereof (to the extent so required by and upon the terms set forth in the Senior Security Agreement) and (b) each Subsidiary Guarantor ratifies and confirms its guaranty of the Obligations provided pursuant to the Subsidiary Guarantee, including without limitation all of the terms and conditions set forth in Article 12 of the Indenture, and each Subsidiary Guarantor acknowledges and agrees that its obligations under the Indenture shall remain unchanged and in full force and effect, notwithstanding the amendment of the Indenture pursuant to the terms of this First Supplemental Indenture and that the obligations of each Subsidiary Guarantor under Article 12 of the Indenture continue to be and remain in full force and effect on and as of the date hereof.

 

   

 

 

Section 5. Acknowledgement of Supplemental Indenture for Senior Convertible Notes. The Holders acknowledge and agree that, concurrently with this First Supplemental Indenture, the Company and the Subsidiary Guarantors are entering into a First Supplemental Indenture to the Indenture, dated as of December 6, 2022, among the Company, the subsidiary guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent, relating to the Company’s Subordinated Secured Convertible Notes due April 6, 2026 (the “Subordinated Supplement”) and the Holders hereby consent to the execution and delivery of such Subordinated Supplement.

 

Section 6. Governing Law. This First Supplemental Indenture, and any dispute, claim or controversy arising under or related to this First Supplemental Indenture, shall be governed by and construed in accordance with the laws of the State of New York (without regard to the conflicts of laws provisions thereof other than Section 5-101 of the General Obligations Law).

 

Section 7. Counterparts. This First Supplemental Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this First Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this First Supplemental Indenture as to the parties hereto and may be used in lieu of the original First Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. The words “execution”, “signed”, “signature,” and words of similar import in this First Supplemental Indenture shall be deemed to include electronic or digital signatures or the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures or a paper based recordkeeping system, as the case may be, to the extent and as provided under applicable law, including the Electronic Signatures in Global and National Commerce Act of 2000 (15 U.S.C. §§ 7001-7006), the Electronic Signatures and Records Act of 1999 (N.Y. State Tech. §§ 301-309).

 

Section 8. Severability. In case any provision of this First Supplemental Indenture or the Indenture is invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby.

 

Section 9. Waiver of Jury Trial; Submission to Jurisdiction. The provisions of Section 14.10 (Waiver of Jury Trial) and Section 14.13 (Submission to Jurisdiction) of the Indenture shall apply to this First Supplemental Indenture, mutatis mutandis.

 

Section 10. Disclaimer. Neither the Trustee nor the Collateral Agent shall be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this First Supplemental Indenture with respect to the Company or any Subsidiary Guarantor or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company and the Subsidiary Guarantors. In entering into this First Supplemental Indenture, the Trustee and the Collateral Agent shall be entitled to the benefit of every provision of the Indenture relating to the conduct or affecting the liability of or affording protection to the Trustee or the Collateral Agent, as applicable, whether or not elsewhere herein so provided.

 

[Signature Page to Follow]

 

   

 

 

IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be duly executed as of the date first above written.

 

 

PROSOMNUS, INC. 

   
   
  By: /s/ Brian B. Dow
    Name: Brian B. Dow
   

Title: Chief Financial Officer 

 

 

 

PROSOMNUS HOLDINGS, INC. 

   
   
  By: /s/ Brian B. Dow
    Name: Brian B. Dow
    Title: Chief Financial Officer

 

 

 

PROSOMNUS SLEEP TECHNOLOGIES, Inc.,  

   
   
  By: /s/ Brian B. Dow
    Name: Brian B. Dow
    Title: Chief Financial Officer

 

[Signature Page to First Supplemental Indenture]

 

   

 

 

  WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee and as Collateral Agent
  By: /s/ Sarah Vilhauer
    Name: Sarah Vilhauer
    Title: Assistant Vice President

 

[Signature Page to First Supplemental Indenture]

 

   

 

Exhibit 4.2

 

FIRST SUPPLEMENTAL INDENTURE

 

dated as of June 29, 2023

 

among

 

ProSomnus, Inc.,

 

the Subsidiary Guarantors Party Hereto

 

and

 

Wilmington Trust, National Association,
as Trustee and Collateral Agent

 

 

 

Subordinated Secured Convertible Notes due April 6, 2026

 

   

 

 

THIS FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), entered into as of June 29, 2023, among (i) ProSomnus, Inc., a Delaware corporation (the “Company”), (ii) ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc. (each, a “Subsidiary Guarantor”), and (iii) Wilmington Trust, National Association, as trustee (in such capacity, the “Trustee”) and collateral agent (“Collateral Agent”).

 

RECITALS

 

WHEREAS, the Company, the Subsidiary Guarantors party thereto and the Trustee and Collateral Agent entered into the Indenture, dated as of December 6, 2022 (the “Indenture”), relating to the Company’s Subordinated Secured Convertible Notes due April 6, 2026 (the “Notes”);

 

WHEREAS, the Company and the Holders of not less than a majority in aggregate principal amount of the Outstanding Notes desire to make certain amendments to the Indenture to, among other things, correct a scrivener’s error in the definition of Conversion Rate, and have delivered to the Company and the Trustee an Act of such Holders approving this First Supplemental Indenture; and

 

WHEREAS, pursuant to Section 8.02 of the Indenture, the Company, the Subsidiary Guarantors, the Trustee and the Collateral Agent are entering into this First Supplemental Indenture.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and intending to be legally bound, the parties to this First Supplemental Indenture hereby agree as follows:

 

Section 1. Defined Terms. Capitalized terms used herein and not otherwise defined herein are used as defined in the Indenture.

 

Section 2. Amendments to Indenture.

 

(a)           The definition of Consolidated EBITDA set forth in Section 1.01 of the Indenture is hereby amended and restated in its entirety as follows:

 

Consolidated EBITDA” means, for any applicable period, the sum of Consolidated Net Income (exclusive of all amounts in respect of any gains and losses realized from Dispositions other than inventory Disposed of in the ordinary course of business), (i) plus the sum, without duplication, of interest expense, depreciation, amortization, non-cash stock-based compensation expenses, any one-time moving expense, any losses from an early extinguishment of indebtedness, acquisition-related expenses, whether or not such acquisition is successful, non-cash changes in the valuation of assets and liabilities as required under GAAP and transaction fees, costs and expenses related to any issuance of equity or debt securities, whether or not successful, and (ii) minus the sum, without duplication, of operating expenses capitalized during such period and to be expensed in a future period to the extent that such expenses were not deducted in determining Consolidated Net Income and would have been deducted in determining Consolidated Net Income if they were not capitalized.

 

(b)           The definition of Conversion Rate set forth in Section 1.01 of the Indenture is hereby amended and restated in its entirety as follows:

 

Conversion Rate” means: 86.95652173913043 shares of Common Stock per $1,000 of the sum of principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto, subject to adjustment as set forth herein, which such Conversion Rate shall be increased and only increased on each Reset Date to equal the greater of (i) 86.95652173913043 per $1,000 of the sum of the principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto, subject to adjustment as set forth herein, and (ii) the number of shares of Common Stock per $1,000 of the sum of the principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto obtained by dividing $1,000 by 105% of the applicable Market Price; provided, however, in no event shall the Conversion Rate be greater than 222.22222222 per $1,000 of the sum of the principal amount of Notes plus accrued interest thereon plus the Make-Whole Amount related thereto, subject to adjustment as set forth herein. The Company shall notify the Holders, the Trustee and the Conversion Agent of the applicable adjustment to the Conversion Rate as of such date (each notice, a “Reset Date Adjustment Notice”). For purposes of clarity, whether or not the Company provides a Reset Date Adjustment Notice, the Holders shall receive a number of shares of Common Stock and retain a principal amount of its Note, plus accrued interest thereon plus the Make-Whole Amount related thereto, based upon the Conversion Rate as adjusted pursuant to this definition, regardless of whether the Holder accurately refers to such Conversion Rate of principal amount of its Notes plus accrued interest thereon plus the Make-Whole Amount related thereto converted in any Conversion Notice. Any adjustment to the Conversion Rate shall be effective on the applicable Reset Date.

 

   

 

 

(c)          The definition of Permitted Indebtedness set forth in Section 1.01 of the Indenture is hereby amended and restated in its entirety as follows:

 

Permitted Indebtedness” means (a) the indebtedness evidenced by the Notes, (b) the Indebtedness existing on the Original Issue Date and set forth on Schedule 3.01(bb) attached to the Purchase Agreement, (c) lease obligations and purchase money indebtedness of up to $3,000,000, in the aggregate, incurred in connection with the acquisition of capital assets and lease obligations with respect to newly acquired or leased assets used in manufacturing the Company’s and its Subsidiaries’ products, (d) indebtedness that (i) is expressly subordinate to the Notes pursuant to a written subordination agreement with the Holders that is acceptable to each Holder in its sole and absolute discretion and (ii) matures at a date later than the 91st day following the Maturity Date, (e) financing for premiums on general business or director and officer insurance up to $3 million per calendar year, and (f) the Senior Debt.

 

(d)          Section 5.17(a) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

(a)       Minimum EBITDA. The Company and its Subsidiaries shall not permit the Consolidated EBITDA as of the last day of any fiscal quarter of the Company, calculated for the period of four (4) consecutive fiscal quarters ended on such date, to be less than (i) for the fiscal quarters ending June 30, 2023, September 30, 2023 and December 31, 2023, ($12,500,000), (ii) for the fiscal quarters ending March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, ($10,000,000) and (iii) for the fiscal quarter ending March 3, 2025 and thereafter, ($7,500,000).

 

(e)           Section 5.17(b) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

   

 

 

(b)       Minimum Revenue. The Company and its Subsidiaries shall not permit the Revenue of the Company and its Subsidiaries on a consolidated basis in accordance with GAAP, as of the last day of any fiscal quarter ending on the dates set forth below and calculated for the period of the last twelve months ending on such date, to be less than the amount set forth below for such date.

  

Fiscal Quarter Ending Minimum Revenue
6/30/2023  $ 22,500,000
9/30/2023  $ 24,000,000
12/31/2023  $ 26,000,000
3/31/2024  $ 25,200,000
6/30/2024  $ 27,000,000
9/30/2024  $ 28,800,000
12/31/2024  $ 31,200,000
3/31/2025  $ 30,240,000
6/30/2025  $ 32,400,000
9/30/2025  $ 34,560,000
12/31/2025 and thereafter  $ 37,440,000

  

Section 3. Reference to and Effect on Indenture. On and after the effective date of this First Supplemental Indenture, each reference in the Indenture to “this Indenture,” “hereunder,” “hereof,” or “herein” shall mean and be a reference to the Indenture as amended and restated by this First Supplemental Indenture unless the context otherwise requires, and every Holder heretofore or hereafter authenticated and delivered shall be bound hereby.

 

Section 4. Reaffirmation. In connection with the execution and delivery of this First Supplemental Indenture, (a) the Company and each Grantor Subsidiary reaffirms, acknowledges, agrees and confirms that it has granted to the Collateral Agent, to the extent so required by and upon the terms set forth in the Subordinated Security Agreement, a security interest in the Collateral in order to secure all of its present and future Obligations and acknowledges and agrees that such security interest, and all Collateral heretofore pledged as security for the Obligations, continues to be and remains in full force and effect on and as of the date hereof (to the extent so required by and upon the terms set forth in the Subordinated Security Agreement) and (b) each Subsidiary Guarantor ratifies and confirms its guaranty of the Obligations provided pursuant to the Subsidiary Guarantee, including without limitation all of the terms and conditions set forth in Article 12 of the Indenture, and each Subsidiary Guarantor acknowledges and agrees that its obligations under the Indenture shall remain unchanged and in full force and effect, notwithstanding the amendment of the Indenture pursuant to the terms of this First Supplemental Indenture and that the obligations of each Subsidiary Guarantor under Article 12 of the Indenture continue to be and remain in full force and effect on and as of the date hereof.

 

Section 5. Acknowledgement of Supplemental Indenture for Senior Convertible Notes. The Holders acknowledge and agree that, concurrently with this First Supplemental Indenture, the Company and the Subsidiary Guarantors are entering into a First Supplemental Indenture to the Indenture, dated as of December 6, 2022, among the Company, the subsidiary guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent, relating to the Company’s Senior Secured Convertible Notes due December 6, 2025 (the “Senior Supplement”) and the Holders hereby consent to the execution and delivery of such Senior Supplement.

 

   

 

 

Section 6. Governing Law. This First Supplemental Indenture, and any dispute, claim or controversy arising under or related to this First Supplemental Indenture, shall be governed by and construed in accordance with the laws of the State of New York (without regard to the conflicts of laws provisions thereof other than Section 5-101 of the General Obligations Law).

 

Section 7. Counterparts. This First Supplemental Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this First Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this First Supplemental Indenture as to the parties hereto and may be used in lieu of the original First Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. The words “execution”, “signed”, “signature,” and words of similar import in this First Supplemental Indenture shall be deemed to include electronic or digital signatures or the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures or a paper based recordkeeping system, as the case may be, to the extent and as provided under applicable law, including the Electronic Signatures in Global and National Commerce Act of 2000 (15 U.S.C. §§ 7001-7006), the Electronic Signatures and Records Act of 1999 (N.Y. State Tech. §§ 301-309).

 

Section 8. Severability. In case any provision of this First Supplemental Indenture or the Indenture is invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby.

 

Section 9. Waiver of Jury Trial; Submission to Jurisdiction. The provisions of Section 14.10 (Waiver of Jury Trial) and Section 14.13 (Submission to Jurisdiction) of the Indenture shall apply to this First Supplemental Indenture, mutatis mutandis.

 

Section 10. Disclaimer. Neither the Trustee nor the Collateral Agent shall be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this First Supplemental Indenture with respect to the Company or any Subsidiary Guarantor or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company and the Subsidiary Guarantors. In entering into this First Supplemental Indenture, the Trustee and the Collateral Agent shall be entitled to the benefit of every provision of the Indenture relating to the conduct or affecting the liability of or affording protection to the Trustee or the Collateral Agent, as applicable, whether or not elsewhere herein so provided.

  

[Signature Page to Follow]

 

   

 

 

IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be duly executed as of the date first above written.

 

 

PROSOMNUS, INC. 

   
   
  By: /s/ Brian B. Dow
    Name: Brian B. Dow
   

Title: Chief Financial Officer  

 

 

 

PROSOMNUS HOLDINGS, INC. 

   
   
  By: /s/ Brian B. Dow
    Name: Brian B. Dow
    Title: Chief Financial Officer

 

 

 

PROSOMNUS SLEEP TECHNOLOGIES, Inc.,  

   
   
  By: /s/ Brian B. Dow
    Name: Brian B. Dow
    Title: Chief Financial Officer

 

[Signature Page to First Supplemental Indenture]

 

   

 

 

 
WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee and as Collateral Agent
   
   
  By: /s/ Sarah Vilhauer
    Name: Sarah Vilhauer
    Title: Assistant Vice President

 

[Signature Page to First Supplemental Indenture]

 

   

 

 

 

 

GRAPHIC 2 tm2320309d2_424b3-img01.jpg GRAPHIC begin 644 tm2320309d2_424b3-img01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBL7Q)X MCMO#MCYLF)+A^(H0V"Q]3Z#WJX0E.2C%7;,ZE2%*#G-V2-JH9;RUA?9+R,*6(=9)TUIYG176JZ?9,HNKVW@+< MCS) N?SJ:WO+6[7=;7,,R^L;AA^E.GMX;J%H;B))8FZHZA@?P->;>)M&C\,7 M*:G;Q3V]L6Q]JLF.Z$G^^AX(/L0.V/6:-.G4]UMI_A_F%>I6I^]&* MFT5R'AOQ3+=R>1=7-M>PD?)>VW !])$ZH?<@"NOK*I2E3E:1K2K1JQN@HHID MDL<0!DD5 > 6.*S-A]%0?;+7_GYA_P"_@J8$$ @Y![BG8+BT444@"BBB@ HH MJH=4T\2>6;^U#_W3,N?RS32;V$VD6Z* 01D'(HI#"BBB@ HHHH **** "BBB M@ HHHH **** "BBB@".XGCMK>6>5ML<:%V/H ,FO!=6U*?6-5GO9B2TK?*O] MU>RCZ"O4OB'>26?AI?+./.F\EOH4?/\ *O+M$C6;7=/C<91KB,,/4;AFO?RR MFH4Y5G_5CY/.ZSJ5H8=>7WO8]=\):9%8Z1 [(OVP1"&9AR1M8G9^!8Y]ZZ"N M9\ W>>1_J9&-=-7C5[^TES;W/IJ$5&E%1VL%175M#>6LMM<1 MB2&52CHW0@U+16.QL?-^M:;>>%O$4]HLTD4L+9BEC8J2AY4@CV_6O3?#/CR2 M33;"34_GA<_9I;CO'*.A;U#*5.?4-7/_ !?@5-?L9P/FDMMI_!C_ (USWA^< MOH&MVCVOW:GT)7%_$*."4 M^'H[H(;=M4B64.<*5.*[?P[;3H'A MEU6)'0_Q*<@BO&H+EK6?2_Y,]>I+GH\RZV_0G.A>!L?ZC2?^_J_XU0\'M'#X MLUJST>3S-!C163:Y>-)CC(0GM][IZ"MC_A O"_\ T!X?^^F_QK8L--LM*M/L MUA;1V\().R,8!/J?4U4JL>5I-N_<%3?,G9*W8XK0M3\<:_I$.I6L^BI#*6"K M*D@88)!SC/I6A9:_K>G>(K31O$,5E(U\I-O/9%L @/JSW%SX@TYS"TES*7Q&<[60 M'H""?\FMZBIIST5EV6OEK8=OG(W0KGKTS^-='XFUFPTK0[MKJ>(.\+K'$6&Z1B, =36W4M>]%SS M26%[.-/E3BS=MZ1M_>4DY'T_^M66^O:[XANYD\+QV:6-NYC>^N\D2,.NP#L/ M7O5/288M+\7-H.C:C+<:=+:2/-"TGF+:OG P>W7I[U/\.[F+3])ET*\=(-1L M[AU>%V 9@3D,/4<_I3E&RG>5/#& M+RR\Q)+R[40PVZG+NS$#@=>.M8>KV$EA%X$L+G#217$<<@ZC.%R/IVITXQER MSE'OIW25Q3QKEY/%TDWQ$M= M-C6H5U MN'*Y)D"%MH/M@9^M8$VJZCX)N+[PW;0/-'@K MX>\4^$K0R>;<.+R6XE_YZ2&,9/\ 3\*(T8QNWJFG;[KW^6WJ-U92LEI9J_W[ M?UT+NN^,;_1O&2V(M5GTV.V$]QL0F1%)(+#GH.#C'3-=C:W5O?6T=S:S)-#( M,HZ'((KCBJO\8&5@&4Z5@@C@C=39E;X?78FMTDE\.W4G[V,?,;-S_$/]D^GM M^_X_F.,Y1;;VO\ =_P!R^+-1_X5BWB+;!]M!QC8=G^NV=,^ MGO7;]J\OMH)+GX%R)$I9@'? ]%G+'] :]%L=3L]0L8[NVN8I(64-N5P0/8^A MJ:\$K\J^TU^5BJ4F[7?1&-'XCDAU/Q,MTBFUTE(I$$:_,08RS9YYZ<=*S;*] M\;:W:1ZC9MHUI;3#?#%(7=MIZ;B.,_YQ2Z)<6=UJWC#4Y2LFER/'$TF"RN$C M*OTZCFH],\)Z// ;GPUXAO[6%SDI:W6Y ?=2,Y^M:6A&]U9Z=+K;\R+RE:S[ M];/NU&_P :\ATNY6SU:SN7^[%.CM] P)KZ (# M@C(/!!KQ+Q7X>ET'59%5&^QR'=!)CC']W/J*]S*ZR<949?+]3Y?/,/*,HXF' M3?Y;'J/@_3SI7AV.RSE8II@C?WE\QBI_$8-;M,HU&I'T.'FITHRCV0445F:_K5OX?T:?4+@C]VOR(3@ MR/V45E&+D[(V;25V>4?%J]2X\4PVR-G[-;J']F8D_P MM9.@P>7X9U&;!,UY M-%:P*.K8.]L#Z[/SJG;:5K/BO4I+I(B[W$N7GD.R,,3TR?Y#)]J]ET+P58Z1 M'8F5C/-:)\F>%#GEGQW.>GH /3->_*K##4XP;NU^G_!/#G1J8ER<=+_D_P#@ M&YI=LUGI-G;.,-# D9^H4"F:E;Z;+]FDU'R1Y$RR0M*^W;(.A'/6KU8&NQVG M]HVL\UW#!.L,L:"[CW0.K;=P). &X'0YQG@BO#C>4[GLM*,$ET-YG5!EF"@D M#)..2<"AF55+,0% R23P!6!=7*-X5L;F2/[+'YMHQ61N(P)H^I/;'?I4>AW%O);A$O;"XE"*2+50I48[C3U)NK(NZO8Z)J)C@U:*SE;_ )9K M,0&_#O\ E45CX2T#39A-:Z5;)*IRKE=Q4^H)SC\*@U#3WU+6[VW'V;RWL8D? MSX/,X+R]!D5NV\(M[:* ,SB- FYNIP,9-)R<8I*3] 24I-M$%S>Z>A>WNKFV M4D8:.611D'U!K$OO"/A%7$MWIUE 6/'S^4#] "!6CJ<,3ZGI):)&)N&R2H.? MW,E4O$,BQZSI#/<6MNO[[Y[I=R?=';@?*LHP3]-PY_6FZL\$VBQ.KQ M269FB,K1X*&/>-Q]-OK[9JQISZ?)<7;V&U@S*99(CE&;&.,<9P!G\*GWE[]W MNK.QO;JW-S%%)/;MYT(8_, MA_O ?E6!9)>"TT R3P- 9QM182&'[J3&6W$'\A5G4[>=M>:[L\?:[:U5D4CB M1=S;HS]<#Z$ ]JIIN6LN_P#D2FE'1&Z?)=5F;RV"_,KG!Q[@U66+3M0N8+]/ M(N);? V\8D>$@J7!; R.,A>OMM]JGDLF^URN:]BZMA8OJ!U)88FN]AB\X:TW"UN)8=TP($4C#+CH1@]:S=$OK3RY;3[5!]I^V77[GS!O_P!< MY^[UZON:R9/!GA>Z?[0=)M3N^;E4N:*YDWJ)\K?*T:L,=CIU@JPK!;6:+\NW"H ?TYS6,WA/PIJKM.NG64I MSAF@.!GWVG&:2](7P58$O'&!]B)>495?WD?)&1Q^(K4M)K>?3I?+NK>? 82/ M8C';L 6.<>^:7O17,F]Q^[+1I":18Z18020Z1%:QQAL2"#!^8?WB.<_6M&N8 MT*:WBU2*TMC!=(;/ N8!M:-4("I*HXW?,<'@\-P*Z>HJ)J6I4&FM HHHK,L* MK7UA:ZE:/:WD*RPOU5OYCT/O5FBFFT[H4HJ2L]CSS6/AS/-!&-+O1'+:OOM) M)&(9 >2A([;N0>V3ZYK7T#5/$]NB6>OZ-+*Z\"\MWC8,/5ES^H_*NLHKHEB9 M3C::O^9A##QI_P /0I7VIQV*\V]W,Y&0L%N[_J!C]:XF_P!-UGQ#?),NDLI4 M_+/J; K'_NP\@?B&/O7H=%*E65/51U)K4)5='-I=E;\]3&T7P^FF 3W-Q)>7 MVW:9Y/X!_=0?PCZ5LT45E.